The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R06 | Antihistamines for systemic use | |
| 3 | R06A | Antihistamines for systemic use | |
| 4 | R06AA | Aminoalkyl ethers | |
| 5 | R06AA04 | Clemastine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 2 mg |
| PAREN - Parenteral | 2 mg |
| Active Ingredient | Description | |
|---|---|---|
| Clemastine |
Clemastine is an H1-receptor antagonist. It inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| TAVEGIL Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
